Expert Interviews on RLT-PSMA

Daniel Tennenbaum, MDRLT | December 1, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
View More
Daniel Tennenbaum, MDRLT | December 1, 2022
Neil Desal, MD, MHS, is interviewed by Daniel Tennenbaum, MD, on the use of PSMA-PET in intermediate risk prostate cancer.
David Ambinder, MDVideo Insights | December 1, 2022
An interview with Preston Sprenkle, MD, Associate Professor of Urology at Yale, on the clinical utility of PSMA imaging.
David Ambinder, MDVideo Insights | December 1, 2022
An interview with Preston Sprenkle, MD, Associate Professor of Urology at Yale, on the clinical utility of PSMA imaging.
GU Oncology Now EditorsRLT | December 1, 2022
Part two of an interview with Russell Szmulewitz, MD on the benefits of PSMA-PET for high-risk and advanced prostate cancer.
GU Oncology Now EditorsRLT | December 2, 2022
Part one of an interview with Russell Szmulewitz, MD on the benefits of PSMA-PET for high-risk and advanced prostate cancer.
Akhil Abraham Saji, MDRLT | December 2, 2022
Dr. Saji continues his interview with Dr. Sonni about using PSMA-PET to understand recurrence risk and inform therapy plans.
Akhil Abraham Saji, MDRLT | December 2, 2022
Akhil Saji, MD, interviews Ida Sonni, MD, about using PSMA-PET to better understand recurrence risk and inform therapy plans.
GU Oncology Now EditorsRLT | December 1, 2022
Dr. Tagawa discusses how PSMA is used in the detection of prostate cancer, the approval of gallium-68 PSMA PET-CT, and more.
GU Oncology Now EditorsRLT | December 1, 2022
Dr. Tagawa discusses clinical trials he's watching for, using PSMA for an initial prostate cancer diagnosis, and more.
Robert DillardRLT | December 2, 2022
Dr. Kishan discusses PSMA-directed imaging and the impact of precision medicine on the treatment of advanced prostate cancer.
Robert DillardRLT | December 2, 2022
Drs. Lenzo and Singh discuss the impact PSMA PET modalities have had in the fight against advanced prostate cancer.
Robert DillardRLT | December 2, 2022
Panel participants discuss PSMA and PSMA PET-based scans for diagnosis and management of patients with prostate cancer.
Robert DillardRLT | December 2, 2022
Dr. Jeremie Calais discusses the future of PSMA PET imaging modalities in prostate cancer with Dr. Agarwal.
GU Oncology Now EditorsRLT | February 28, 2023
Drs. Agarwal and Tagawa discuss PSMA imaging and the future of CT scans in the follow-up of metastatic prostate cancer.
GU Oncology Now EditorsRLT | February 28, 2023
Drs. Agarwal and Tward discuss the use of PSMA imaging for oncologists and urologists dealing with localized prostate cancer.
GU Oncology Now EditorsRoundtable | February 28, 2023
Drs. Agarwal and Calais review the basics of PSMA imaging of prostate cancer and what makes it unique.
Robert DillardRLT | December 2, 2022
Dr. Delphine Chen discusses the use of PSMA-targeted PET imaging modalities for detecting prostate cancer.
Robert DillardRLT | December 2, 2022
Dr. Karnes explains why he believes the PSMA scan is a game changer for prostate cancer detection and its benefits.
Robert DillardRLT | December 2, 2022
Dr. Hope provides expert insight on using PSMA imaging for the staging and management of prostate cancer.
Robert DillardRLT | December 1, 2022
Dr. Fanti discusses an article he co-authored on imaging technologies for men with rising prostate-specific antigen.
Advertisement
Advertisement
Advertisement
Advertisement